UM vitae - Physicians Database Loginphydatabase.med.miami.edu/Documents/CV/NBishopricUM vitae... · Web viewKubasiak L, Discher DJ, Bishopric NH, and Webster KA (2000). Over-expression

CURRICULUM VITAE

1. Date: April 30, 2007

PERSONAL

2. Name: Nanette Hahr Bishopric, M.D., F.A.C.C., F.A.H.A.

3. Home Phone: Private

4. Office Phone: 305-243-6775

5. Home Address: Private

6. Academic Rank: Professor, June 1, 2004Tenured, June 1, 2002

7. Primary Department: Molecular and Cellular Pharmacology

8. Secondary Departments: Medicine and PediatricsMember, Sylvester Cancer CenterFaculty, John T. Macdonald Center for Medical Genetics

9. Citizenship: U.S.

10. Visa Type: N/A

HIGHER EDUCATION

11. Institutional:

1969-1973 B.A., Magna Cum Laude, Music (Performance)Duke University, Durham, North Carolina

1974-1975 Cell Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts

1975-1979 M.D., Duke University School of MedicineDurham, North Carolina

12. Non-Institutional:

A. Clinical Training

1979-1980 University of Florida, Gainesville, FLIntern, Dept. of Medicine (Dr. James E. McGuigan, Chairman)

1980-1981 Duke University, Durham, North CarolinaFellow in Hematology/Oncology (Dr. Wendell Rosse, Chief)

1981-1983 University of Florida, Gainesville, Florida

Nanette H. Bishopric, M.D. Curriculum Vitae

Assistant Resident, Dept. of Medicine (Dr. James E. McGuigan, Chairman)

1983-1985 University of California at San FranciscoClinical Fellow in Cardiology (Dr. William Parmley, Chief)

13. Certification

1983 American Board of Internal Medicine

1985 American Board of Internal Medicine (Cardiology)

1992 National Board Examination Part III re-certification

Medical Licensure (active): State of California #G50082; State of Florida #37475

EXPERIENCE

14. Academic

1988-1989 Instructor in Medicine, University of California at San Francisco

1989-1996 Assistant Professor of Medicine, University of California at San Francisco

1992-1996 Clinical Assistant Professor of Medicine, Stanford University

1996-2004 Associate Professor of Pharmacology and Medicine, University of Miami, Miami, Florida

1998-present Director, UM-MHRI Cardiovascular Genetics Program

2002-2007 Associate Professor of Pediatrics, University of Miami, Miami, Florida

2004-present Professor of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida

2004-present Professor of Medicine, Division of Cardiology, University of Miami, Miami, Florida

2004-present Professor of Pediatrics, University of Miami, Miami, Florida

15. Non-Academic

Hospital Appointments:

2005-present Cedars Medical Center, Staff Physician

1999-present Jackson Memorial Hospital, Staff Physician UMMG; Teaching

1989-1991 Consulting Molecular Biologist, SRI International, Menlo Park, California

1992-1996 Senior Molecular Biologist, Life Sciences Division

1992-1997 Consultant in Health Sciences, Business and Policy Group

2


SRI International, Menlo Park, California

Representative Consulting Projects:

Consultant, modeling the market diffusion of a new antithrombotic agent in the U.K. (1996)Consultant, identification of novel technologies for licensing and acquisition (for major U.S. pharmaceutical client, 1997-1998)Consultant, assessment of biological targets for lead development compounds (for major U.K. pharmaceutical client, 1996-1997)Expert witness for the defense, major US pharmaceutical company, drug outcomes litigation (2004-2007)Expert witness for the defense, US generic drug manufacturer, drug outcomes litigation (2006)Expert witness for the defense, major US pharmaceutical company, drug outcomes litigation (2005-present)Expert witness, tobacco-related diseases litigation (2007-)

16. Military

N/A

PUBLICATIONS

17. Books, reviews and monographs:

1. Webster KA and Bishopric NH. Cardiomyocyte apoptosis. In: The Heart in Biology and Disease, ed. E. Bittar, Vol. 16 (2007, in preparation).

2. Jain S, Rodrigues CO, Webster KA, Bishopric NH (2007). New therapeutic targets to prevent cardiomyocyte apoptosis. J. Pharmacol Exp Therap, in press.

3. Bishopric NH, Andreka P and Webster KA. Apoptosis and risk with the use of calcium antagonists. In: Calcium Channel Antagonists in Clinical Medicine, 3rd edition, ed. M. Epstein. Hanley and Belfus, Philadelphia, 2002.

4. Webster KA, Prentice H, Bishopric NH. Redox regulation of zinc finger transcription factors. In: Antioxidants and Redox Signaling, 3: 535-548, 2001.

5. Webster KA, Discher DJ, Hernandez O, Yamashita K, and Bishopric NH. A glycolytic pathway to apoptosis of hypoxic cardiac myocytes: molecular pathways of increased acid production. In: Oxygen Sensing: Molecules to Man, S. Lahiri & N. Prabhakar, eds., Kluwer. Academic Press, London, UK, 2000.

6. Webster KA and Bishopric NH. Molecular aspects and gene therapy prospects for diastolic failure. In: Cardiology Clinics, SJ Kovacs, ed., W.B. Saunders & Co. volume 18(3): 621-635, 2000.

3


7. Webster KA, Discher DJ and Bishopric NH. Induction of proto-oncogenes and lipid second messengers in hypoxic cardiac myocytes. In: Hypoxia and Molecular Medicine, J. R. Sutton, C. S. Houston and G. Coates, eds. Queen City Printers, Inc., Burlington VT, pp 98-111, 1993

8. Bishopric NH, Wade R, Gahlmann R and Kedes LH. Gene expression during skeletal and cardiac muscle development. In: The Heart and Cardiovascular System, second edition, H.A. Fozzard et al., eds. Raven Press, Ltd., New York, pp 1587-1598, 1992

9. Bishopric NH, Long CS, Waspe LE, Simpson PC and Ordahl CP (1989). The molecular biology of cardiac myocyte hypertrophy. Studies using a cell culture model. In: Cellular and Molecular Biology of Muscle Development, UCLA Symposia Vol. 93 (New Series), L. H. Kedes and F. E. Stockdale, eds., Alan R. Liss, Inc., New York, pp 399-412, 1989

10. Simpson PC, Bishopric NH, Coughlin SR, Karliner J, Ordahl CP, Starksen N, Tsao T, White N and Williams LT: Dual trophic effects of the ß1-adrenergic receptor in cultured neonatal rat heart muscle cells. J Mol Cell Cardiol 18 (Suppl 5): 45, 1986

11. Bishopric NH, Mehta J and Mehta P. Platelet activation and platelet-suppressive drugs. In: Platelets and Prostaglandins in Cardiovascular Disease, Mehta J and Mehta P, eds., Futura Publishing Co., Mt. Kisco, NY: 1981.

18. Juried or refereed journal articles or exhibitions:

(in preparation or submitted)

1. Shehadeh L, Sharma S., Pessanha M, Wei JQ, Webster KA, and Bishopric NH (2007). Cardiac myocyte p300 levels regulate angiogenesis during myocardial hypertrophy through Sox4. In preparation.

2. Bishopric NH, Hilfiker D, Drexler H, Dzau V, Sugden P (2007). Facts about factors: paracrine signalling by stem cells in cardiac repair. In preparation.

3. Rodrigues CO, Wei JQ, Li J, Llanos A, Webster KA, Bishopric NH (2007). Accelerated aging in a mouse model of p300 histone acetylase deficiency. In preparation.

4. Papapetropoulos S et al. Gene expression of MT1 & MT2 receptors in Parkinson’s disease human post mortem brain (2007). J Pineal Res, submitted.

5. Wei JQ, Mitrani J, Pessanha M, Shehadeh L, Slepak TI, Webster KA and Bishopric NH (2007). Stoichiometric regulation of cardiac hypertrophy by acetyltransferase p300. Genes Devel, submitted.

6. Wilson A, Shehadeh LA, Gosink M, Tsinoremas NF, Bishopric NH and Webster KA (2007). Age and maturity confer distinctive gene expression profiles in murine bone marrow mesenchymal stem cells. Stem Cell, submitted.

(in press or published)7. Ley JJ, Prado R, Wei JQ, Bishopric NH, Ginsberg MD (2007). Neuroprotective antioxidant STAZN

protects against myocardial ischemia/reperfusion injury. Biochem. Pharmacol, in press.

4


8. Graham R, Thompson JW, Wei JQ, Bishopric NH and Webster KA (2007). Regulation of Bnip3 death pathways by calcium, phosphorylation and hypoxia-reoxygenation. Antiox Redox Signal, 9(9):1309-16

9. Tran TH, Andreka P, Rodrigues CO, Webster KA and Bishopric NH (2007). Jun kinase delays caspase-9 activation by interaction with the apoptosome. J Biol Chem, 282(28):20340-50. Epub 2007 May 4.

10. Rodrigues CO, Shehadeh L, Webster KA and Bishopric NH (2007). Myocyte deficiency as a target in the treatment of cardiomyopathy. Progress in Pediatric Cardiology, in press.

11. Shehadeh LA, Bishopric NH, Wilson A, Gosink M, Tsinoremas N, and Webster KA (2007). Immune remodeling of mesenchymal stem cells during osteoblastic differentiation. Nature Biotechnology Short Reports, in press.

12. Papapetropoulos S, Adi N, Shehadeh L, Mash D, Bishopric NH. (2007). Expression of -synuclein mRNA in Parkinson’s Disease. Movement Disorders, 22(7):1057-9.

13. Frazier DP, Wilson A, Dougherty C, Li, H, Bishopric NH, Webster KA (2007). PKC-delta and TAK-1 are intermediates in the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol. 292(4):H1675-84. Epub 2007 Jan 5.

14. Miller TE, You L, Myerburg RJ, Benke PJ, Bishopric NH (2007). Whole blood RNA offers a rapid, comprehensive approach to genetic diagnosis of cardiovascular diseases. Genetics in Medicine 9(1): 23-33.

15. Webster KA, Graham RM, Thompson JW, Spiga MG, Frazier DP, Wilson A, Bishopric NH (2006). Redox stress and the contributions of BH3-only proteins to infarction. (2006) Antioxid Redox Signal 8(9-10):1667-1676.

16. Frazier DP, Wilson A, Graham RM, Thompson JW, Bishopric NH, Webster KA (2006). Acidosis regulates the stability, hydrophobicity, and activity of the BH3-only protein Bnip3. Antioxid Redox Signal. 8(9-10):1625-1634.

17. Rodrigues CO, White EL, King ML, Nerlick S, Bishopric N, and Cleveland JL (2006). A MYC-twist-slug regulatory circuit directing neural crest determination affects angiogenesis. Nature Biotechnology Short Reports, 17:78

18. Spiga M-G, Layman H, Wilson AD, Jia Y, Bishopric NH, Andreopoulos FM, and Webster KA (2006). Delivery of VEGF165 with hypoxia-regulated adeno-associated virus (AAV) serotype 9 produces stable conduction vessels in mouse ischemic limbs. Nature Biotechnology Short Reports, 17:85.

19. Pessanha M, Wei JQ, Shehadeh L, Faysal J, Webster KA, and Bishopric NH (2006). Cardiac myocyte p300 levels regulate myocardial angiogenesis. Nature Biotechnology Short Reports, 17:87.

20. Bishopric, NH (2005). Evolution of the heart from bacteria to man. Annals of the New York Academy of Sciences 1047:13-29.

21. Webster KA, Graham RM, Bishopric NH (2005). BNip3 and signal-specific programmed death in the heart. J Mol Cell Cardiol 38(1):35-45.

5


22. Turner MS, Haywood GA, Andreka P, You L, Martin PE, Evans WH, Webster KA, Bishopric NH (2004). Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circ Res 95(7):726-733.

23. Graham RM, Frazier DP, Thompson JW, Haliko S, Li H, Wasserlauf BJ, Spiga MG, Bishopric NH and Webster KA (2004). A unique pathway of cardiac myocyte death cased by hypoxia-acidosis. J Exp Biol 207(18):3189-3200.

24. Andreka P, Tran T, Webster KA, Bishopric NH (2004). Nitric oxide and promotion of cardiac myocyte apoptosis. Molecular and Cellular Biochemistry 263:35-53.

25. Andreka P, Nadhazi Z, Muzes G, Szantho G, Vandor L, Konya L, Turner MS, Tulassay Z and Bishopric NH (2004). Possible therapeutic targets in cardiac myocyte apoptosis. Current Pharmaceutical Design 10(20):2445-2461.

26. Miller TE, Estrella E, Myerburg RJ, Garcia de Viera J, Moreno N, Rusconi P, Ahearn ME, Baumbach L, Kurlansky P, Wolff G and Bishopric NH (2004). Recurrent third trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation 109(24):3029-3034.

27. Webster KA, Bishopric NH (2003). Apoptosis inhibitors for heart disease. Circulation 108(24):2954-6.

28. Myerburg RJ and Bishopric NH (2003). Transplantation of stem cells to the heart: are there risks counterbalancing anticipated benefits? J Cardiovasc Electrophysiol 14(8):849-50.

29. Kubasiak L, Hernandez L, Bishopric NH and Webster KA (2002). Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 99:12825-12930.

30. Bishopric NH and Webster KA (2002). Preventing apoptosis with thioredoxin: ASK me how. Circ Res 90(12):1237-1239.

31. Graham R, Bishopric NH and Webster KA. (2002) Gene and cell-based therapy for heart disease. IUBMB Life 54(2):59-66.

32. Bishopric NH. A Thousand Times NO. (2002) J Mol Cell Cardiol 34; 601-606.

33. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, and Bishopric NH. (2002) Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 105:2429-2434.

34. Dougherty C, Kubasiak LA, Prentice H, Andreka P, Bishopric NH and Webster KA. (2002) Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 362:561-571.

35. Bishopric NH (2002). Angiotensin signaling and apoptosis in the neonatal heart: necessary evils? Pediatric Res 52(3):322-4.

36. Bishopric NH, Andreka P, Slepak T, and Webster KA (2001). Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opinion in Pharmacology 2: 141-150.

37. Andreka P, Nadhazi Z, Muzes G, Bishopric NH (2001). Molecular regulation of myocardial apoptosis. (Review in Hungarian) Orv Hetil 142:1717-1724.

6


38. Andreka P, Zang J, Dougherty C, Slepak T, Webster KA, and Bishopric NH (2001) Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 88: 305-312.

39. Yamashita Y, Discher DJ, Hu J, Bishopric NH, and Webster KA (2001). Molecular regulation of the endothelin-1 gene promoter by hypoxia: contributions of HIF-1, AP-1, GATA-2, and CBP/p300. J Biol Chem 276:12645-12653.

40. Yamashita Y, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P and Webster KA (2001). Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts over-expressing IGF-1. Circ Res 88: 609-614.

41. Webster KA, Prentice H, Bishopric NH (2001). Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal 3:535-548.

42. Slepak T, Webster KA, Prentice H, O’Dowd A, Hicks M and Bishopric NH (2001). Control of cardiac-specific transcription by p300/CBP through myocyte enhancer factor-2D. J Biol Chem 276: 7575-7585.

43. Leri A, Fiordaliso F, Setoguchi M, Limana F, Bishopric NH, Kajstura J, Webster KA and Anversa P (2000). Inhibition of p53 function prevents renin-angiotensin system activation and stretch-mediated myocyte apoptosis. Am J Pathology 157:843-857.

44. Hernandez O, Discher DJ, Bishopric NH and Webster KA (2000). Rapid Activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes Circ Res 86:198-204.

45. Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B and Bishopric NH (1999). Hypoxia-activated apoptosis of cardiac myocytes requires a pH shift and is independent of p53. J Clinical Invest 104: 239-252.

46. Discher DJ, Bishopric NH and Webster KA (1999). High Frequency Rearrangement of a Multiple Copy Enhancer in Plasmid Vectors: Practical Considerations. Biotechniques 26:1026-1030.

47. Webster KA, Discher DJ, Kaiser S, Sato B, Zang J, Hernandez O and Bishopric NH (1999). Induction of apoptosis by hypoxia requires reoxygenation or acidosis and is independent of p53. J Clin Invest 104: 239-252.

48. Ing D, Zang J, Dzau V, Webster KA and Bishopric NH (1999). Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak and Bcl-x. Circ Res 84: 21-33.

49. Webster KA and Bishopric NH (1998). Adaptaciones de miocitos cardiacos prematuros a la hipoxia, isquemia, y reoxígenación Revista Chilena de Cardiología Vol. 14.

50. Discher DJ, Bishopric NH, Wu XS, Petersen C and Webster KA (1998). Hypoxia regulates -enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273: 26087-26093.

51. Gullestad L, Haywood G, Aass H, Ross H, Yee G, Geiran O, Kjekshus J, Simonsen S, Bishopric NH and Fowler M (1998). Expression of angiotensin II receptor subtypes in heart transplant recipients. Cardiovasc Res 38: 340-347.

52. Prentice H, Bishopric NH, Hicks MN, Discher DJ, Wu XS, Wylie AA and Webster KA (1997). Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 35(3): 567-574.

7


53. Webster KA, Discher DJ and Bishopric NH (1997). Models of Heart Disease: Early and late gene responses to hypoxia, ischemia, and reoxygenation. Acta Andina 6:89-107.

54. Wu CF, Bishopric NH, and Pratt RE (1997). A sensitive nonradioactive method for the determination of internucleosomal cleavage associated with apoptosis. Biotechniques 23(5): 839-843.

55. Wu C-F, Bishopric NH and Pratt RE (1997). ANP induces apoptosis in rat cardiac myocytes. J Biol Chem 272: 14860-14866.

56. Eschenhagen T, Remmers U, Scholz H, Wattchow J, Weil J, Zimmerman W, Schäfer H, Bishopric NH, Wakatsuki T and Elson EL (1997). Three dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J 11:683-694.

57. Bishopric NH, Zeng GQ, Sato B and Webster KA (1997). Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus. J Biol Chem 272: 20584-20594.

58. Ellison K, Bishopric N, Webster K, Morishita R, Gibbons GH, Kaneda Y, Sato B and Dzau V (1996). Enhanced effectiveness of HVJ mediated gene transfer into cultured rat neonatal cardiac myocytes. J Mol Cell Cardiol 28: 1385-1399.

59. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacker PR, Bishopric NH, Cooke JP, McKenna WJ and Fowler MB (1996). Expression of inducible nitric oxide synthase in human heart failure. Circulation 93: 1087-1094.

60. Wu XS, Bishopric NH, Discher DJ, Murphy BJ and Webster KA (1996). Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 16(3): 1035-1046.

61. Webster KA, Bodí I, Wu X, Discher D, and Bishopric NH (1995). Regulation of the endothelin-1 gene by hypoxia is endothelial cell-specific and requires tyrosine kinase. Cardiovasc Res 30: 975-984.

62. Webster KA, Discher D and Bishopric NH (1995). Cardioprotection in an in vitro model of hypoxic preconditioning. J Mol Cell Cardiol 27: 453-458.

63. Webster KA, Discher DJ and Bishopric NH (1994). Regulation of Fos and Jun immediate-early genes by redox or metabolic stress in cardiac myocytes. Circ Res 74: 679-686.

64. Webster KA, Discher DJ and Bishopric NH (1993). Induction and nuclear accumulation of Fos and Jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 268: 16852-16859.

65. Webster KA, Bodi I, Discher D, McNamara JP, Tracy M and Bishopric NH (1993). Negative lusitropy and abnormal calcium handling in hypoxic cardiac myocytes exposed to the calcium sensitizer EMD53998. J Mol Cell Cardiol 25: 747-751.

66. Bishopric NH, Jayasena V, and Webster KA (1992). Positive regulation of the skeletal -actin gene by Fos and Jun. J Biol Chem 267: 25535-25540.

67. Bishopric NH, Sato B and Webster KA (1992). -adrenergic regulation of a myocardial actin gene via a cyclic AMP-independent pathway. J Biol Chem 267: 20932-20936.

68. Webster KA and Bishopric NH (1992). Molecular regulation of cardiac myocyte adaptations to chronic hypoxia. J Mol Cell Cardiol 24: 741-752.

8


69. Sartorelli V, Hong NA, Bishopric NH and Kedes LH (1992). Myocardial activation of the human cardiac -actin promoter by helix-loop-helix proteins. Proc Natl Acad Sci 89: 4047-4051.

70. Bishopric NH and Kedes LH (1992). Adrenergic regulation of the skeletal -actin gene promoter during myocardial cell hypertrophy. Proc Natl Acad Sci 88: 2132-2136.

71. Bishopric NH, Simpson PC and Ordahl CP (1987). Induction of the skeletal -actin gene in 1-adrenoceptor mediated hypertrophy of rat cardiac myocytes. J Clin Invest 80: 1194-1199.

72. Starksen NF, Simpson PC, Bishopric NH, Coughlin SR, Lee WMF, Escobedo JA and Williams LT (1986). Cardiac myocyte hypertrophy is associated with c-myc proto-oncogene expression. Proc Natl Acad Sci 83: 8348-8350.

73. Bishopric NH, Cohen HJ and Lefkowitz RJ (1980). -adrenergic receptors in lymphocyte subpopulations. J Allergy Clin Immunol 65: 29-33.

74. Newman, KD, Williams LT, Bishopric NH and Lefkowitz RJ (1978). Identification of the platelet 1-adrenergic receptor by direct binding of (3H)-dihydroergocryptine. J Clin Invest 61: 395-402.

19. Other works, publications and abstracts:

Abstracts (selected).

1. Rodrigues CO, Shehadeh LA, Calero K, Bishopric NH (2007). Transcriptional variability in cardiac stem cell clones. 4th Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences, July 30 - August 2, 2007, Keystone Conference Center, Keystone, Colorado.

2. Ali MAM, Sung MM, Tran T, Crawford B, Rosenfelt CS, Sawicki G, Bishopric NH, Schulz R (2007). Inhibitors of matrix metalloproteinases prevent H2O2-mediated cardiac myocyte membrane permeabilization and death. Western Pharmacological Society, Banff, Alberta, Canada, March 2007.

3. Wei JQ, Llanos A, Rodrigues C, Steen D, Webster KA and Bishopric NH (2006). Cardioprotection by p300 during myocardial ischemia-reperfusion and infarction in vivo. Circulation 114 (18): II-98.

4. Thompson JW, Graham RM, Bishopric NH and Webster KA (2006). Programmed death by hypoxia-acidosis involves BNip3- and ERK-dependent activation of histone acetyltransferase (HAT) and genomic reprogramming. Circulation 114 (18): II-296.

5. Wierenga KJ, Miller TE, Bishopric NH, Benke PJ (2006). A novel splice site mutation associated with Barth syndrome. Presented at American College of Medical Genetics 2006 Annual Meeting. Online at http://submissions.miracd.com/ACMG/ContentInfo.aspx?conID=245

6. Webster KA, Spiga M-G, Wilson AA, Bishopric NH, Eton D, Jia Y, Cesar L, Haliko S, Yu H, Lieber BB, Laymen H, Andreopoulos FM, Wei J, Yeasky T. Combination cell and gene therapy for peripheral ischemia using myoblasts and stem cells engineered with conditionally sliced genes. Miami-Nature Biotechnology Winter Symposia on Angiogenesis in Cancer and Vascular Disease, Feb. 4-8, 2006. Nature Biotechnology Short Reports, Vol 17.

9

http://submissions.miracd.com/ACMG/ContentInfo.aspx?conID=245


7. Tran T, Andreka P Webster KA and Bishopric NH (2005). Cytoprotection by Jun kinase is mediated through direct inhibition of the apoptosome. American Heart Association National Meeting, November 2005; Circulation,

8. Thompson JW, Graham RM, Bishopric NH and Webster KA (2005). BNip3 promotes nuclear translocation of mitochondrial and lysosomal DNAses: protection from genomic fragmentation by a HH-4 peptide or calpain inhibitors. Circulation 112 (17): II-285.

9. Baumbach L, Miller T, Cocilova S, Travers H, Elliott S, Mont E, Myerburg R, Bishopric N (2005). Genetic Complexities of Molecular Diagnosis for Ventricular Arrhythmias. American Society of Human Genetics 55th Annual Meeting Abstracts (Salt Lake City, Utah), October 25-29, 2005, in press.

10. Shehadeh L, Wei JQ, Liebovitch L, Jirsa V, Fallahi M, Tsinoremas N, Prentice H, Bishopric N. Transcription Factor Networks in Cardiac Hypertrophy. BioFlorida Annual Conference, “Building the Vision,” Delray Beach, FL presented October 24-25, 2005.

11. Miller TE, You L, Benke PJ, Bishopric N (2005). Rapid Screening of Complex Genetic Disorders Associated with Heart Disease Using Direct Whole Blood RT-PCR. J Am Coll Cardiol 45(3) Suppl A: 323A, #1142-245. (ACC 3/8/2005)

12. Wei JQ, Mitrani J, Llanos A, Webster KA, Bishopric (2005). Role of the Chromatin Remodelling Enzyme p300 In Heart Failure Progression and Survival. J Am Coll Cardiol 45(3) Suppl A: 174A, #1160-147. (ACC 3/8/2005)

13. TE Miller, TV Pham, MJ Smets, L You, A Bassett, P Kurlansky, LL Baumbach-Reardon, RJ Myerburg, NH Bishopric (2004). Novel Mutations (S338F and F339S) in Cardiac KvLQT1 S6 Domain Hinder KvLQT1 – KCNE1 Co-Assembly. Circulation 110(17): III-16 #67. (AHA 11/2004)

14. Webster KA, Gounis MJ, Spiga M.-G., Graham RM, Haliko S, Wilson A, Lieber BB, Bishopric NH and Wakhloo NH (2004). Optimized therapeutic angiogenesis for peripheral ischemia using stem cells transduced with an ischemia-regulated conditionally silenced AAV. Late-Breaking Developments in Stem Cell Biology and Cardiac Growth Regulation, America Heart Association National Meeting, New Orleans, LA 11/8/04.

15. Li HF, Bishopric NH, Webster KA (2004). C-Jun N-terminal Kinase (JNK) promotes apoptosis at reperfusion under energy-limiting conditions by phosphorylating IRS-1 and blocking insulin signaling to Akt/PKB. Circulation 110(17): III-58 #268. (AHA 11/2004)

16. L Baumbach, T Miller, H Travers, L You, ME Ahearn, W Lanier, E Estrella, S Elliott, R Myerburg, N Bishopric (2004. Complexities of molecular diagnosis for ventricular arrhythmias. American Society of Human Genetics 54th Annual Meeting Abstracts (Toronto, Canada), October 26-30, 2004, p. 390, #2141.

17. Wei JQ, Slepak T, Pessanha M, Faysal J, Andreka P, Webster KA and Bishopric NH. (2003) Transcription coactivator p300 is a critical regulator of cardiac hypertrophy. Miami Nature Biotechnology Short Reports, 14:51.

18. Miller T, Estrella E, You LJ, Lanier W, Young ML, Baumbach L, Myerburg RJ, Bishopric NH (2003). Compound heterozygous mutation of both alpha and beta subunits of IKs is associated with Romano-Ward Syndrome. Circulation 108: IV-182.

19. Miller T, Estrella E, You LJ, Lanier W, Young ML, Baumbach L, Myerburg RJ, Bishopric NH (2003). Compound heterozygous mutation of both alpha and beta subunits of IKs is associated

10


with Romano-Ward Syndrome. American J for Human Genetics (Suppl) 73(5): 552, #2251 (ASHG 11/03).

20. Wei JQ, Slepak T, Pessanha M, Webster KA, Bishopric NH (2003). Adenovirus target protein p300 mediates cardiac hypertrophy and heart failure. Nature Biotechnology Short Reports 14: 22.

21. Tran TH, Andreka P, Dougherty C, Webster KA and Bishopric NH. (2003) C-Jun N-terminal kinase protects cardiomyocytes against stress-induced apoptosis by direct interaction with APAF-1. Miami Nature Biotechnology Short Reports 14:64.

22. Miller T, Moreno N, Estrella E, Ahearn ME, Garcia J, Rusconi P, Wolff G, Kurlansky P, Myerburg R, Baumbach L, and Bishopric NH (2002). Recurrent pregnancies associated with fetal sudden death in a mother mosaic for an SCN5A mutation. Circulation 106, II-700. (Oral presentation at the 75th Annual Scientific Sessions meeting of the American Heart Association, Chicago IL, 11/2002)

23. Dougherty C, Graham RM, Prentice H, Bishopric NH, Webster KA (2002). C-Jun N-terminal kinase functions as a bioenergetic sensor that determines cardiac myocyte fate during hypoxia-reoxygenation. Circulation 106 (19) (Suppl II):II-130.

24. Wei JQ, Pessanha M, Faysal J, Webster KA, Bishopric NH (2002). Adenovirus target protein p300 mediates cardiomyopathy and heart failure. Circulation 106: II-231-232.

25. II-231-232.Turner MS, Haywood GA, Dougherty C, Andreka P, Evans WH, Webster KA, Bishopric NH. Regulation of connexin 43 phosphorylation by ATP during hypoxia/reoxygenation and metabolic inhibition in cardiac myocytes. Circulation 106: II-313

26. Miller T, Moreno N, Estrella E, Ahearn ME, Rusconi P, Wolff G, Kurlansky P, Myerburg R, Baumbach L and Bishopric NH (2002). Repeated pregnancies associated with late term fetal loss and sudden death in a mother mosaic for a SCN5A mutation. Platform Presentation, 52nd Annual Meeting of the American Society of Human Genetics, Baltimore, MD.

27. Baumbach L, Miller T, Estrella E, Ahearn ME, Kurlansky P, Myerburg R and Bishopric NH (2002). A cardiac ion channel (KVLQT1) mutation predisposes to drug-induced arrhythmia: direct evidence of genetic susceptibility to an acquired disorder. Platform presentation, American Society of Medical Genetics Annual Meeting, San Diego, CA.

28. Baumbach L, Miller T, Estrella E, Ahearn ME, Kurlansky P, Myerburg R, Bishopric NH (2002). A cardiac ion channel (KVLQT1) mutation predisposes to drug-induced arrhythmia: direct evidence of genetic susceptibility to an acquired disorder. Asia Pacific Scientific Forum: The Genomic Revolution: Bench to Bedside to Community and the 42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention. Abs #100523 (Platform presentation).

29. Baumbach L, Basterrechea H, Estrella E, Myerburg R, Wolff G, Bishopric NH (2001). Am J Human Genetics (Suppl) 69:544, # 2126.

30. Turner MS, Discher DJ, Webster KA, Bishopric NH (2001). Different regulation of Connexin 43 in cardiac myocytes by hypoxia and ischemia. Circulation 104: Supp 17:206.

31. Dougherty CJ, Kubasiak LA, Discher DJ, Prentice H, Bishopric NH, Webster KA (2001). Coupled electron flow through mitochondrial complex II initiates a survival pathway through c-Jun N-Terminal kinase in reoxygenated cardiac myocytes. Circulation 104: Supp 17:445.

11


32. Andreka P, Dougherty CJ, Slepak TI, Webster KA, Bishopric NH (2001). The apoptosome is a target of Jun kinase in nitric oxide-induced cardiac myocyte apoptosis. Circulation 104: Supp 17: 681.

33. Kubasiak LA, Discher DJ, Bishopric NH and Webster KA (2001). Hypoxia-acidosis activated apoptosis of cardiac myocytes is mediated by MPTP opening and BNIP3 activation. Circulation Suppl 104: 17: 976.

34. Bishopric NH, Basterrechea H, Myerburg RJ and Baumbach L (2001). Genotype-phenotype correlations in long QT syndrome. Presented at the Annual Clinical Genetics Meeting, Miami, FL, March 2, 2001.

35. Turner MS, Haywood GA, Evans WH, Webster KA and Bishopric NH (2001). Hypoxia regulates connexin 43 content in synchronously contracting cardiac myocytes. J Am Coll Cardiol 37 (2 Suppl A): 308.

36. Dougherty C, Prentice H, Hernandez H, Andreka P, Bishopric NH and Webster KA (2000). Activation of c-Jun N-terminal kinase through the Rac1/cdc42-TAK-1 pathway promotes survival of reoxygenated cardiomyocytes. Hypertension J 3.

37. Andreka P, Zang J, Dougherty C, Slepak T, Webster KA, Bishopric NH (2000). The role of nitric oxide-induced myocardial apoptosis in the development of heart failure. Circulation 102(18): II-9.

38. Slepak TI, Webster KA, Xang J, Prentice H, Hicks MN and Bishopric NH (2000). Molecular basis of the cardiac-specific effect of p300 are mediated exclusively by MEF-2D and are independent of GATA-4. Circulation 102(18): II-219.

39. Discher DJ, Wasserlauf B, Bishopric NH and Webster KA (2000). Conditional silencing as a means to suppress basal expression and augment the ‘therapeutic differential’ of gene therapy vectors targeted to ischemic tissues. Circulation 102(18): II-145.

40. Yamashita K, Discher DJ, Kajstura J, Anversa P, Bishopric NH and Webster KA (2000). IGF-1 over-expressing transgenic mice are resistant to ischemia-reperfusion-induced apoptosis through enhanced activation of the PI-3 kinase-Akt pathway. Circulation 102(18): II-214.

41. Kubasiak L, Discher DJ, Bishopric NH, and Webster KA (2000). Over-expression of hypoxia-regulated DT-diaphorase (NADH-quinone reductase) gene protects cardiac myocytes from hypoxia-reoxygenation induced apoptosis. Circulation 102(18): II-84.

42. Kubasiak L, Hernandez OM, Discher DJ, Bishopric NH, and Webster KA (2000). Role of mitochondrial complexes II and III and the permeability transition pore respectively in hypoxia-reoxygenation and hypoxia-acidosis cell death pathways of cardiac myocytes. Circulation 102(18): II-9.

43. Dougherty C, Prentice H, Andreka P, Bishopric NH, and Webster KA (2000). Activation of c-Jun N-terminal Kinase through the Rac1/cdc42-TAK-1 pathway promotes survival of reoxygenated cardiac myocytes. Circulation 102(18): II-168.

44. Zang J, Slepak, T, Webster KA, and Bishopric, NH (1999). Role of mitogen activated protein kinases ERK1/2 and JNK 1/2 in nitric oxide-induced cardiac myocyte apoptosis. Circulation 99 Suppl.

45. Yamashita K, Discher D, Bishopric NH, and Webster KA (1999). Induction of endothelin-1 by hypoxia is mediated by cooperative physical interactions between HIF-1, AP-1, GATA-2, and CAAT binding factors. Circulation 99 Suppl.

12


46. Webster KA, Discher DJ, Hernandez OH, Yamashita K, Dougherty C, and Bishopric NH (2000). Hypoxia, Gene Expression, and Gene Therapy. J Comp Biochem Physiol (Suppl)

47. Webster KA, Discher DJ, Hernandez OH, Yamashita K, Dougherty C, and Bishopric NH (1999). Hypoxia and Reoxygenation-Mediated Signaling Pathways to Apoptosis. In: Genomics of Oxygen Sensing, Plenum Press.

48. Leri A, Fiordaliso F, Manabu S., Discher D., Bishopric NH, Webster KA, and Anversa P (1999). Inhibition of p53 function prevents stretch-mediated activation of the myocyte renin-angiotensin system and apoptosis. Circulation 99 Suppl.

49. Hernandez O, Discher D, Bishopric NH, and Webster KA (1999). Activation of Neutral Sphingomyelinase ceramide, and JNK precede apoptosis in hypoxia-reoxygenated cardiac myocytes. Circulation 99 Suppl.

50. Hernandez O, Discher DJ, Bishopric NH, and Webster KA (1999). Activation of neutral sphingomyelinase and JNK precede apoptosis following reoxygenation of cardiac myocytes. Miami Nature Biology Short Reports 10:38-38.

51. Dougherty C, Discher D, Bishopric NH, and Webster, KA (1999). C-Jun N-Terminal kinase protects cardiac myocytes from reoxygenation-mediated apoptosis. Circulation 99 Suppl.

52. Bishopric NH, Slepak TI, Zang J, and Webster KA (1999). Transcriptional integrator p300 and MEF-2D activate cardiac-specific transcription of the human skeletal actin promoter. Scientific Conference on Molecular Cellular and Integrated Approaches to the Failing Heart, Salt Lake City UT.

53. Anderson KM, Nerurkar S, Zang J, Webster KA and Bishopric NH (1999). Induction and decline of p300/CBP availability during cardiac hypertrophy and failure in the SHHR rat. Scientific Conf. on Molecular Cellular and Integrated Approaches to the Failing Heart, Salt Lake City, UT.

54. Slepak T, Webster KA, Zang J, and Bishopric NH (1999). Cardiac regulation of the human skeletal actin promoter by GATA-4 and MEF-2 involves competition for p300 at a distal tissue-specific element. Scientific Conference on Molecular Cellular and Integrated Approaches to the Failing Heart, Salt Lake City, UT.

55. Zang J, Ing D, Dzau VJ, Webster KA, and Bishopric NH (1998). Nitric oxide activations of cardiomyocyte apoptosis, MAPK/ERK and Jun kinases exhibit differential dose-dependence and cGMP sensitivity. Circulation 98 (17): I-742.

56. Hu J, Discher DJ, Hernandez O, Bishopric NH, and Webster KA (1998). Hypoxia-Inducible Factor-1 and GATA-2 are both required for the positive endothelial cell-specific activation of the endothelin-1 gene by hypoxia. Circulation 98: I-331.

57. Daviet L, Lehtonen JYA, Hayashida W, Grandchamp J, Bishopric NH, Horiuchi M, and Dzau VJ (1998). Antagonistic actions of angiotensin II type 1 vs. type 2 receptors on rat cardiomyocyte apoptosis. Circulation 96(17): I-741.

58. Discher D, Sato B, Kaiser S, Hernandez O, Murphy BJ, Bishopric NH, and Webster KA (1998). Differential regulation of antioxidant gene expression in hypoxic cardiac myocytes. Circulation 98 (17): I-124.

59. Bishopric NH, Kaiser S, Discher D, Hernandez O, Zang J, Sato B, and Webster KA (1998). p53-Independent induction of apoptosis by hypoxia-reoxygenation of isolated cardiac myocytes. Circulation 98(17): I-743.

13


60. Ing D, Zang J, Webster KA, Dzau V, Bishopric NH (1998). Interleukin -1β induces cardiac myocyte apoptosis through a cyclic GMP-dependent pathway. Circulation 98(17)

61. Webster KA, Discher DJ, and Bishopric NH (1998). Hypoxia activates the transcription of Sp1-dependent genes by downregulating Sp3-mediated competitive repression. Presented at Keystone Symposium on Molecular Biology of the Cardiovascular System, Steamboat Springs CO, 1998

62. Bishopric NH, Kaiser S, Zang J, Discher D, Sato B, and Webster KA (1998). p53 is dispensable for redox-stress-induced cardiac myocyte apoptosis. Presented at Keystone Symposium on Molecular Biology of the Cardiovascular System, Steamboat Springs CO.

63. Bishopric NH, Discher DJ, and Webster KA (1997). Activation of SAPK/JNK in cardiac myocytes treated with a calcium sensitizing agent, EMD53998. Circulation 96: I-361.

64. Bishopric NH, Zang J, Zeng GQ, Webster KA (1997). p300 transactivates the human skeletal actin promoter in cardiac myocytes via a distal promoter region. Circulation 96: I-674.

65. Wu XS, Fowler MB, Gullestad L, Webster KA, Bishopric NH (1997). Induction of c-jun expression in human dilated cardiomyopathy. Circulation 96.

66. Wu XS, Discher DJ, Bishopric NH, and Webster KA (1996). Developmental regulation of redox-sensitive Sp1 isoforms in the heart. Circulation 94: I-483.

67. Wu C-F, Pratt RE, and Bishopric NH (1996). Cyclic AMP and cyclic GMP exert opposing effects on cardiac myocyte apoptosis. Circulation 94: I-282.

68. Wu C-F, Bishopric NH, and Pratt RE (1996). Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 27: 384A.

69. Zeng GQ, Webster KA, Sato B, Bishopric NH (1996). E1A induces both p53-dependent and -independent apoptosis in cardiac myocytes. Circulation 94: I-158.

70. Gullestad L, Haywood G, Aass H, Ross H, Yee G, Geiran O, Kjekshus J, Simonsen S, Fowler M, and Bishopric NH (1996). Expression of angiotensin II receptor subtypes in heart transplant recipients. Presented at European Society of Cardiology, Birmingham, U.K. August 1996.

71. McDonald P, Hicks MN, Webster KA, Wylie A, Cobbe SM, Bishopric NH, and Prentice H (1995). Regulation of foreign gene expression in models of myocardial gene therapy. Presented at the Cellular Engineering Conference, San Diego, CA, August 1995.

72. McDonald P, Hicks MN, Webster KA, Wylie A, Cobbe SM, Bishopric NH, and Prentice H (1995). Induced activity of the skeletal α-actin promoter in ischemic/reperfused myocardium. J Mol Cell Cardiol 27:A255.

73. Webster KA, Bódi I, Sato B, Discher DJ, and Bishopric NH (1995). Induction of stress response and hypertrophy-related genes by the positive inotropic, calcium-sensitizing agent EMD53998. Circulation 92(8):I-43.

20. Other works accepted for publication:

Patent application #08/880, 342, continuation.

PROFESSIONAL

14


21. Funded Research Performed (as P.I. unless otherwise noted)

A. Extramural support (prior years)

1988-1992 Research Associate of the Veterans Administration

1988-1991 and Veterans Administration Merit Review Award 1991-1994

1990-1993 and American Heart Association (Calif. Affil.) Grants-in-Aid1993-1996

1990-1993 and University of California Tobacco-Related Diseases Research1993-1996 Program Grant Co-P.I

1993-1999 Grant R-01-HL37475, “Beta-Adrenergic regulation of a myocardial actin gene” Direct $780,000/5 years, 40% effort.

2000-2001 GlaxoSmithKline research fund, $37,000 total direct costs

1998-2002 American Heart Association Established Investigator Award$272,727 total direct costs

2001-2003 American Heart Association Grant-In-Aid (Florida-PR Affiliate)$100,000 total costs

15


B. Current, Pending and Recent Extramural Support

Grant Title Project Role

Amount (direct)

Period Funding Agency

Grant # R-01-HL71094,“Transcription programming in cardiac growth”

P.I.(40%)

Year 1250,000(total)1,000,000

07/01/03-06/30/08percentile 20.7, resubmitted 7/1/07

NIH/NHLBI

Trans-Atlantic Network of Excellence Grant, “Adaptation and Maladaptation in Cardiac Hypertrophy, Failure and Regeneration”

CoreMember(30%)

Year 2138,000(total)720,000

10/1/05-9/30/10

Leducq Foundation,Paris, France

Trans-Atlantic Network of Excellence Grant, “Preventing Sudden Cardiac Death”R. Myerburg, M.D.

Affiliate Member(6%)

Year 2140,000(total)1,000,000

10/1/05-9/30/10

Leducq Foundation,Paris, France

NRSA Postdoctoral Fellowship “Transcription Factor Networks in Cardiac Hypertrophy”Lina Shehadeh, Ph.D.

Sponsor Year 260,000

12/1/05-11/1/08

N.I.H.

Grant # R-01-HL44578, "Pathways of apoptosis in hypoxic cardiac myocytes"Keith A. Webster, Ph.D.

Co-I.(5%)

Year 5 171,158(total)951,232

09/01/96-08/30/08

N.I.H./N.H.L.B.I.

Team Sciences AwardKeith A. Webster, Ph.D.

Co-I(5%)

Year 1 7/01/07-6/30/09

Florida Biomedical Research Council

Scientist Development Grant, “Mechanisms of cardiac stem cell survival” C. Rodrigues, Ph.D.

Sponsor (yr 1)65,000(total)$260,000

06/01/07-05/31/11

American Heart Association (National)

NRSA Predoctoral Fellowship “Body Burden of PAHs and Cardiovascular Disease in the United States”John D. Clark, III

Co-sponsor Year 1$34,032

06/01/07-05/31/10

N.I.H./N.H.L.B.I.

NIH R-01 “Epigenetics of Aging and Cell Renewal”

P.I.(40%)

(yr 1)250,000(direct)1,250,000

In preparation for October 2007

N.I.H./N.H.L.B.I./N.I.A.

Recently Completed:Genotype-Phenotype Correlations in Long QT Syndrome (renewed)

Co-I.(10%)

(yr 4) 55,000(total)110,000

7/1/01-12/30/05

American Heart Association (FL-PR affil.)

Grant #R-01-HL69812-01, “Regulated therapeutic angiogenesis to treat ischemic disease”

Co-I.(5%)

(yr. 3)$250,000 annually

04/01/03-03/31/07

N.I.H./N.H.L.B.I.

Cardiovascular Genetics Center Grant;"Sudden Death and Cardiomyopathy” (renewed 2x)

P.I. (yr 1)136,000(total)2,064,528

4/01/99-3/31/07

Florida Heart ResearchInstitute, Miami, FL

16


22. Editorial Responsibilities:Editorial Board, Circulation Research (2000-present)Editorial Board, Circulation (2003, 2005-present)Editorial Board, Journal of the American College of Cardiology (2005-present)Editorial Board, Journal of Molecular and Cellular Cardiology (2001-present)

Reviewer for: American Journal of PhysiologyBasic Research in CardiologyBiochemistryBiochemical PharmacologyCardiovascular ResearchCirculation ResearchCirculationComparative Physiology and BiophysicsJournal of Applied PhysiologyJournal of Biological Chemistry Journal of Clinical Investigation Journal of the American College of CardiologyJournal of Molecular and Cellular Cardiology

Molecular and Cellular BiologyPediatric ResearchPhysica A

23. Professional and Honorary Organizations (current)

Founding Fellow, American Heart Association, 2001American Heart Association Councils for Basic Science and Clinical CardiologyFellow, American College of CardiologyAmerican Federation for Clinical ResearchAmerican Association for the Advancement of ScienceInternational Academy of Cardiovascular Science – American Section, Council MemberEuropean Society of Cardiology

24. Honors and Awards:

1969 National Merit Scholarship Finalist

1973 Phi Beta Kappa

1985 Merck/American College of Cardiology Fellowship Award American Heart Association Postdoctoral FellowshipNational Institutes of Health NRSA (#HL07475)

1987 American Heart Association Post-doctoral Fellowship

1993 SRI International Technical Excellence Award

1999 First Prize, UM/Sylvester Cancer Center Research Competition

2005 Researcher of the Year, Florida Chapter, American College of Cardiology

25. Post-Doctoral Fellowships

17


1978-1979 Research assistant in the laboratory of Dr. Robert J. Lefkowitz, Duke University, Durham, North Carolina. Research topics: - and -adrenoceptor identification by radioligand binding to platelets and lymphocytes and correlation with adenyl cyclase activity; histamine receptor analysis by radiolabelled antagonist binding; production and analysis of a putative anti-ß-adrenoceptor antibody.

1985-1988 Postdoctoral fellow in the laboratory of Dr. Charles P. Ordahl, University of California, San Francisco. Research interests: Molecular biology of cardiac muscle gene expression, regulation of gene expression by norepinephrine.

1988-1989 Visiting Scientist in the laboratory of Dr. Laurence H. Kedes, Stanford University, Palo Alto, California. Research interests: Expression of human skeletal actin and rat myosin heavy chain genes in transfected cardiac myocytes; regulation of bioenergetic genes by oxygen availability in cardiomyocytes; effects of E1A and MyoD1 proteins on cardiac myocyte gene expression.

26. Other Professional Activities

2007 Member, American Heart Association (National) Peer Review Group, Basic Sciences

2007 Member, American Heart Association National Committee on Women and Minorities (nominated)

2006 Session moderator, AHA Annual Scientific Sessions, “Molecular Biology of Cardiac Development,” Chicago, IL, McCormick Place, Nov. 14, 2006

2006 Chair of session: “Interventional Cardiology: cell and gene therapy,” 8th International Dead Sea Symposium & 17th Rappaport Symposium Joint Mtg., Tel Aviv, Israel, Hilton Convention Center, October 17, 2006.

2006 Representative of ACC to Johns Hopkins University Genetics and Public Policy Center meeting on development of practice guidelines for genetic testing, Bethesda, MD, February 1, Hyatt Regency Bethesda.

2005-2008 Regular Member, NIH CSR, Myocardial Ischemia and Metabolism Study Section

2004-2006 Member and Vice Chair, Research Committee, American Heart Association Florida-Puerto Rico Affiliate

2004-2005 Ad Hoc Member, NIH Center for Scientific Review. Cardiovascular Sciences IRG, SRA, Myocardial Ischemia and Metabolism Study Section, July and September 2004; February 2005.

2002-2005 Member, the Katz Young Investigator Prize Selection Committee, AHA Council on Basic Cardiovascular Sciences

2004 26th Annual Meeting of the ISHR (International Society for Heart Research): Bench to Bedside and Back: Exploring New Paradigms - A Multinational Perspective of Cardiovascular Research in North America, Cancun, Mexico, May 2-5, 2004

18


2003 Symposium Moderator, “Regulating Myocardial Growth: Survival and Function”. Heart Failure Society of America, Las Vegas, NV. September 22, 2003

2003 Peer Review Committee Member, American Heart Association (National)

2002 Invited Session Moderator, “Transcriptional Regulation in Cardiac Hypertrophy,” American Heart Association Scientific Sessions, November 18, 2002 Chicago, IL

2001-2002 Faculty Member and Abstract Judge, AstraZeneca Cardiovascular Young Investigator’s Forum

1999-2002 Member, American Heart Association Southeastern-Ohio Affiliate Peer Review Committee

1996-present Session Moderator (various), American Heart Association National Meetings

1998-Present Member, University of Miami Medical Group

2001 Platform Speaker, Heart Failure Society of America, Washington DC, September 9-12

2001 Session Moderator, “Oxidant Signaling in Cardiac Pathophysiology”, American Heart Association National Meeting, Anaheim, CA

2001 Chairman, AHA Student Scholars Program Review Committee

1999-2001 Member, American College of Cardiology Career Development Awards Program (National) Review Committee- Student Scholars in Cardiovascular Disease and Stroke

1998-2000 Abstract Grader, American Heart Association Annual Scientific Session Program Committee

Member, American Heart Association (National) Peer Review Committee

1997 Session Moderator, American College of Cardiology National Meeting

1997-2000 Invited Lecturer, Dept. of Molecular Physiology, Stanford University

1996-1998 Member, NIH Program Project Review Committee

1995-1998 Member, Research Program Review Committee, Dept. of Veterans Affairs

Invited Lectures (since 1997):

19


“Molecular correlates of the growth/death decision in cardiac myocytes”. Presented at the 2nd International Workshop on Cardiac Cells in Culture: Molecular Mechanisms of Hypertrophy, Monte Veritá, Ascona, Switzerland, March 5, 1997

“Myocardial stress”. Presented at Eidgenossen Technische Hochschule- Zurich, Switzerland August 13, 1997

“Molecular insights on cardiac remodelling”. Presented at Workshop on Cardiovascular Genetics, SmithKline Beecham Pharmaceuticals, November 17, 1997

“Modulation of apoptosis by survival factors in the cardiac myocyte”. Presented at the Third Annual International Conference on Heart Failure, sponsored by International Business Communications, Philadelphia, PA. December 10, 1997

“Programmed cell death in cardiovascular disease”. Presented at Medical Grand Rounds, Department of Medicine, University of Miami, December 17, 1997

“Role of nitric oxide in the modulation of cardiac myocyte apoptosis.” Presented at Eli Lilly Pharmaceuticals, January 28, 1998

“Modulation of apoptosis by cardiac growth factors.” Presented at Conference on Vascular and Myocardial Aspects of Ischemic Heart Disease, sponsored by American Heart Association, Incline Village, Nevada, February 23, 1998

“Hypertrophic cardiomyopathy. Clinical and molecular aspects.” Presented at Department of Molecular and Cellular Physiology, Stanford University School of Medicine, February 27, 1998

“The role of apoptosis in the cardiovascular system.” Presented at The Maryland Club, Baltimore, MD, April 15, 1998

“Aging, apoptosis and the heart.” Keynote address, CardioPulmonary Seminar 1998, Sarasota Memorial Hospital, Sarasota FL, July 17, 1998

“Adenovirus E1A and the cardiac myocyte phenotype.” International Society for Heart Failure Research, Ann Arbor MI, August 10, 1998

Chair of session, “Subcellular Abnormalities in Heart Failure,” Second Annual Meeting of the Heart Failure Society of America, Boca Raton FL, September 16, 1998

"Regulation of apoptosis by hypoxia and reoxygenation." Presented at the Second International Meeting on Pathophysiology of Stunning, Hibernation and Preconditioning, sponsored by European Society of Cardiology, Taormina, Sicily, Italy, October 16, 1998

"Gene regulation of the cardiac myocytes." Symposium on New Frontiers in Heart Failure Research, NYU School of Medicine, Key Biscayne FL, October 31, 1998

20


“Hypertrophic cardiomyopathy. Clinical and molecular aspects.” Presented at Department of Molecular and Cellular Physiology, Stanford University School of Medicine, February 22, 1999

“NO, free radicals and cardiac myocyte apoptosis.” Presented at Mini Symposium on Metabolic Regulation of Cardiac Gene Expression, University of Texas at Houston, March 5, 1999

“Signal transduction in ischemic cell death.” Presented at the Scientific Conference on Molecular, Cellular and Integrated Physiological Approaches to the Failing Heart, Salt Lake City, UT, August 21, 1999

“Redox stress and Apoptosis." American Heart Association Scientific Conference on Molecular, Cellular, and Integrated Physiological Approaches to the Failing Heart. Salt Lake City, Utah. August 1999

“Nitric Oxide and Cardiac Signal Transduction.” Texas A & M University, Department of Physiology. September 1999

“Molecular and Clinical Aspects of Hypertrophic Cardiomyopathy." Stanford University, Department of Molecular and Cellular Physiology. February 2000

“p300 and Cardiac Transcriptional Control." Albert Einstein College of Medicine, Division of Cardiology, March 2000

“Cardiac Remodelling at the Molecular Level.” Heart Failure Summit, 2000. Invited Speaker. University of Toronto, Canada, June 7, 2000

“Redox stress and mechanisms of myocardial apoptosis." International Society for Heart Research, 22nd Meeting, Louisville, Kentucky, July 2000

“Apoptosis and Redox Stress,” Sylvester Comprehensive Cancer Center, Tumor Biology Seminar Series, October 2000

“Mechanisms of Angiogenesis.” Surgical Oncology Seminar Series, University of Miami, February 8, 2001

Expert Panelist, C.A.R.E. Foundation Symposium, Ft. Lauderdale, FL. “Everything you always wanted to know about Long QT…but didn’t know whom to ask,” March 16, 2001

“Hypertrophic Cardiomyopathy and Familial Sudden Death.” C.A.R.E. Foundation Symposium, Ft. Myers, Florida, March 17, 2001

“Molecular Mechanisms of Cardiac Growth and Death," University of Miami Dept. of Molecular and Cellular Pharmacology Seminar Series, April 19, 2001

“Nitric Oxide and Myocyte Cell Fate.” American Heart Association Research Symposium, Dallas, Texas, May 5, 2001

21


“Redox Stress and Heart Failure: Role of stress-activated protein kinases.” Heart Failure Society of America National Meeting, Washington DC, September 2001

“Role of HIF-1 in Ischemia.” Platform speaker, American Heart Association Scientific Sessions 2001, Anaheim, California, November 11-14, 2001

“Transcription factor-opathy: a genetic model for the transition from hypertrophy to heart failure,” Florida Atlantic University, January 2002

"Nitric Oxide-Mediated Cardiac Myocyte Apoptosis," Symposium on Advances in Cardiovascular Research – Clinical & Basic Sciences and Workshop – Genome Based Resources for Identification of Cardiovascular Genes, University of the West Indies, St. Augustine, Trinidad, March 5, 2002

"Viral Oncogenes and Dilated Cardiomyopathy," Symposium on Advances in Cardiovascular Research – Clinical & Basic Sciences and Workshop – Genome Based Resources for Identification of Cardiovascular Genes, University of the West Indies, St. Augustine, Trinidad, March 6, 2002

"Genetics and Genetic Models of Dilated Cardiomyopathy," University of Miami School of Medicine, Department of Medicine Medical Grand Rounds, March 13, 2002

“The Genetic Diagnosis of Sudden Death Risk,” BioFlorida, Miami, Florida, June 5, 2002

“Stress and Death in the Ischemic Heart,” American Heart Association symposium, Snowbird, Utah, August 24, 2002

"Oxidative Stress as a Trigger for Cardiac Myocyte Apoptosis," Heart Failure Society of America, September 2002

"Chromatin Remodelling and Heart Failure,” Winters Center for Heart Failure Research, Baylor College of Medicine, Houston, TX, January 7, 2003.

"Adenovirus target protein p300 mediates cardiac hypertrophy and heart failure." Miami Nature Biotechnology Winter Symposium, February 3, 2003.

“Atherosclerosis as an autoimmune disorder,” Genetics Journal Club, Department of Pediatrics, University of Miami, March 6, 2003.

“Transcription programming in a genetic model of heart failure,” University of Winnipeg, Canada, March 10, 2003

“Transcription Coactivator p300 is Critical Regulator of Cardiac Hypertrophy,” Pediatrics/Genetics weekly conference series, University of Miami School of Medicine, April 8, 2003

“The impact of diabetes on vascular disease,” Jackson Memorial Hospital in-service lecture, May 23, 2003.

22


“Cytoskeletal signal transduction and cardiomyopathy,” Cardiomyopathy in Muscular Dystrophy Workshop, Muscular Dystrophy Association, Tucson, AZ. September 2003.

“Signalling cell death by hypoxia and oxidative stress in cardiac myocytes,” European Society of Hematology/MD Anderson 4th Annual Conference on Mechanisms of Cell Death and Disease, Cancun, Mexico, November 2003.

"Transcription factor p300: a chromosome-modifying regulator of heart growth and failure," Department of Medicine, University of Miami School of Medicine, April 6, 2004.

ACC News Release (2004). Commentary on “Genes Linked to Heart Attacks More Common Among African Americans,” posted online on July 7, 2004 at the URL address: http://www.acc.org/media/releases/highlights/2004/july04/genes.htm

“p300 Chromatin Remodeling and Growth Control in Normal Tissue,” Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, July 30, 2004.

Session entitled “Regulators of Cell Death, Survival and Function,” (1) Chair: Bishopric NH. Heart Failure Society of America Annual Meeting, Toronto, Canada, September 14, 2004.

Session 3 “Failure and Intervention” (1) Chair: Bishopric NH / Holtz J, Heart-Failure in the Elderly: Cellular Mechanisms and Therapy (2nd Annual Halle Meeting on the Ageing Heart), Martin-Luther University of Halle-Wittenberg, Nov. 20, 2004

“ROS and other molecular mediators of apoptotic signalling in the failing human heart,” Session 2 - Oxidative stress and ageing, Heart-Failure in the Elderly: Cellular Mechanisms and Therapy (2. Halle Meeting on the Ageing Heart), Martin-Luther University of Halle-Wittenberg, Nov. 20, 2004

"p300- a cardiac transcription super-factor“, presented at Medizinische Hochschule Hannover, Abt. Kardiologie und Angiologie, Hannover, Germany, Nov. 17, 2004

“Connexins between sudden death and heart failure,” Department of Molecular and Cellular Pharmacology Seminar, University of Miami School of Medicine, December 2, 2004.

“Evolution of the heart from bacteria to man,” in session on Cardiac Cell Development, 3rd Larry & Horti Fairberg Workshop – The Communicative Cardiac Cell, Sintra, Portugal, January 15-19, 2005.

“Jun kinase interacts with APAF1 and inhibits Caspase-9 activation induced by oxidative stress,” Miami-Nature Biotechnology Winter Symposia on Signal Transduction in Cancer, poster presentation, February 5-9, 2005.

“Complexities of molecular diagnosis for ventricular arrhythmias,” Masters of Pediatrics Poster Session, Division of Medical Genetics/John T. Macdonald Fdn. Center for Medical Genetics, Miller School of Medicine at the University of Miami

“Novel mutations (S338F & F339S) in cardiac KvLQT1 S6 domain hinder KvLQT1-KCNE1 coassembly,” Masters of Pediatrics Poster Session, Division of Medical Genetics/John T.

23

http://www.acc.org/media/releases/highlights/2004/july04/genes.htm


Macdonald Fdn. Center for Medical Genetics, Miller School of Medicine, University of Miami, Bal Harbor, FL, January 27, 2005

Attendee, ESH-UT MD Anderson Cancer Center International Conference On Mechanisms Of Cell Death And Disease: Advances In Therapeutic Intervention And Drug Development, Cascais, Portugal, October 22-25, 2004

“The Role of the BNip 3 Pathway in Apoptosis”, Heart Failure Society of America Annual Scientific Meeting, Boca Raton, FL, September 20, 2005

“Molecular connections in aging and heart failure”, Cardiovascular Ageing: from molecular biology to clinical perspectives (2nd Annual Halle Meeting on the Ageing Heart), Martin-Luther University of Halle-Wittenberg, Germany, September 24, 2005

Co-Chair of Session: “Tissue Protection During Ageing,” Cardiovascular Ageing: from molecular biology to clinical perspectives (2nd Annual Halle Meeting on the Ageing Heart), Martin-Luther University of Halle-Wittenberg, Germany, September 24, 2005

“Genetic Complexities of Molecular Diagnosis for Ventricular Arrhythmias” presented poster for Research Update, Dr. John T. Macdonald Foundation Center for Medical Genetics and Miami GeneCure Diagnostic Laboratories of the University of Miami Miller School of Medicine, Country Club of Coral Gables, Coral Gables, FL, November 8, 2005

Poster Judge for AHA 2005 Scientific Sessions, “Stem/Progenitor Cells in Cardiac Repair II,” Dallas, TX, November 13, 2005

Co-Moderator for AHA 2005 Scientific Sessions AOP.38.2a, “Molecular and Cellular Mechanisms of Myocardial Apoptosis,” Dallas, TX, November 15, 2005

“Apoptosis in Congestive Heart Failure,” Invited Speaker, AHA Scientific Sessions, Dallas, TX, November 15, 2005

“Reciprocal control of growth and aging by the adenovirus target protein 300.” Distinguished Cardiovascular Lectureship Series, University of California at Los Angeles, December 5, 2005

“Cardiac myocyte p300 levels regulate myocardial angiogenesis,” short report, Miami-Nature Biotechnology Winter Symposia on Angiogenesis in Cancer and Vascular Disease, February 4-8, 2006.

“p300 prevents aging: a role in stem cell maintenance?” Cardiovascular Research Seminar series, New York Medical College, New York, NY, February 15, 2006.

“The apoptosome as a target for Jun Kinase during cardiac myocyte apoptosis”. Visiting Speaker, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, University of Manitoba, Winnipeg, Canada, February 21-22, 2006

“p300 in Cardiac Growth and Regeneration,” Fondation Leducq Annual Network Meeting Hannover Germany, May 6, 2006

“The Sudden Death Database: Needs and Obstacles,” Fondation Leducq Semi-Annual Network Meeting, Opio, France, June 18, 2006

24


“Mechanisms and targets in cardiac myocyte apoptosis”, 8th International Dead Sea Symposium & 17th Rappaport Symposium Joint Mtg., Tel Aviv, Israel, Hilton Convention Center, October 15 through 18, 2006.

“The Reference Population Project”. University of Miami McDonald Center for Genetics, October 25, 2006

“Cell- and gene-based mechanisms in the pathogenesis and treatment of cardiomyopathy”, presented at Idiopathic and Primary Cardiomyopathy in Children: Research, Directions and Strategies Conference, Bethesda, MD, January 25, 2007.

“Evolution of the heart”, University of South Florida College of Engineering, Department of Bioengineering, February 9, 2007

“Cardiac signaling and apoptosis”, Heart Failure Association of the European Society of

Cardiology, Hamburg, Germany, June 11, 2007

“Modulation of apoptosis and heart failure risk” XIX World Congress of the ISHR, Bologna, Italy, June 22-26, 2007.

27. Teaching Awards Receivednone

28. Teaching Specialization

Molecular and Cellular Pharmacology (Cardiovascular diseases)General Cardiology (Outpatient Cardiology clinic and inpatient Cardiology consult service, Jackson Memorial Hospital). Medical Genetics

a., b. Courses Taught and Scheduled (May, 2005 - June, 2006):

“Angiogenesis” Lecture, MDB 665, Tumor Biology Course and Small Group Discussion class (approximately 4 hours preparation and 4 hours class time) University of Miami School of Medicine, October, 2006

Cardiology, Consult Attending, June (1/2 month) 2006, approximately 30 hours of cardiology fellow oversight and teaching

Cardiology, Consult Attending, May 2006, approximately 60 hours of cardiology fellow oversight and teaching

Molecular and Cellular Pharmacology, Spring 2006 MCP 632, Cardiovascular Pharmacology (3 credit, 15 week course)

2005-2006 Curriculum, Cardiovascular System (CVS) MODULE, May 10, 2006, Graduate course for medical students, 1 hr lecture, Drugs for Heart Failure.

2005-2006 Curriculum, Cardiovascular System (CVS) MODULE, May 9, 2006, Graduate course for medical students, 1 hr lecture, Hypertrophic Cardiomyopathy.

25


2006-2006 Curriculum, Cardiovascular System (CVS) MODULE, May 2, 2006, Graduate course for medical students, 1 hr lecture, Drug Treatment of Angina Pectoris.

2005-2006 Curriculum, Cardiovascular System (CVS) MODULE, April 18, 2006, Graduate course for medical students, 1 hr lecture, Cardiac Hypertrophy.

2005-2006 Curriculum, Cardiovascular System (CVS) MODULE, April 12, 2006, Graduate course for medical students, 1 hr lecture, Positive Inotropic Drugs.

Cardiology, Consult Attending, March 2006, approximately 60 hours of cardiology fellow oversight and teaching

Cardiology, Consult Attending, December (1/2 month) 2005, approximately 30 hours of cardiology fellow oversight and teaching

“Angiogenesis” Lecture, MDB 665, Tumor Biology Course and Small Group Discussion class (approximately 4 hours preparation and 4 hours class time) University of Miami School of Medicine, November, 2005

Molecular and Cellular Pharmacology Core Course 2005, Small Group Discussion class, (approximately 1 hour preparation and 2 hours class time) University of Miami Miller School of Medicine, October 5, 2005

Cardiovascular Pharmacology course director, 2002-present; 30 hours of Graduate student lectures and teaching annually.

Cardiovascular Journal Club director, 2001-2005. 12 hours of graduate and postdoctoral fellow teaching and contact time annually.

UM-JMH Cardiology Outpatient Clinic, Co-director, 75 contact/teaching hours with cardiology fellow annually.

29. Trainees:

Name Dates of Training Degree, Institution/Current Position

Kristin Ellison, M.D. 1993-1995 M.D., Tufts University, M.D.Assistant Professor and Staff Electrophysiologist, Brown University Medical School

Project: “Fusigenic liposome-mediated transfection into cardiac myocytes”

Douglas J. Ing, M.D. 1995-1996 M.D., McGill School of MedicineClinical Studies Resource Centre MemberDivision of Clinical Investigation & Human PhysiologyToronto General Research Institute

Project: “Nitric oxide as an apoptosis effector in cardiac myocytes”

Can-Fang Wu, Ph.D. 1995-1996 Ph.D., U.C.L.A.Research Assistant Professor, Stanford University

Project: “Atrial natriuretic peptide as an apoptosis effector in cardiac myocytes”

26


Xiao-Su Wu, Ph.D. 1995-1996 Ph.D., Beijing, ChinaStaff Scientist, Roche Palo Alto, Palo Alto, California

Project: “Upregulation of proto-oncogenes in human heart failure”

Guy Haywood, M.D. 1994-1995 Consulting Cardiologist, Southwest Cardiothoracic Centre, Plymouth, UK.

Project: “Induction of iNOS in dilated cardiomyopathy”

Guo-Qing Zeng, Ph.D. 1994-1996 Ph.D., Paris, France, Assistant Professor,University of North Carolina School of Medicine

Project: “Regulation of cardiac myocyte differentiation and mitosis by adenoviral oncoprotein E1A”

Lars Gullestad, M.D., Ph.D. 1995-1997 M.D., Ph.D., University of Oslo, Senior Cardiologist, Rikshospitalet, University Hospital, Oslo, Norway

Project: “Regulation of iNOS and Angiotensin receptor subtypes in heart failure”

Jie Zang, M.D. 1996- 1999 M.D., ChinaResearch Associate, University of Miami

Project: “Mechanisms and effectors of nitric oxide-mediated apoptosis”

Sandrine Hardouin, Ph.D. 1997-1998 Ph.D., Institute Pasteur, Paris, FrancePostdoctoral Fellow, Department of Pharmacology, University of Washington, Seattle

Project: “Oxidative stress and Beta adrenoceptor-mediated apoptosis”

Peter Andreka, M.D. 1998-2002 M.D., Semmelweis University School of MedicineChief, Hungarian Institute of Cardiology, Budapest, Hungary

Project: “Jun kinase and the mitochondrial pathway for cardiac myocyte death”

Monica Pessanha, PhD 2002-2003 Ph.D., Federal University FluminenseOn leave from University of Miami

Project: “Cellular hypertrophy in p300-mediated cardiac growth”

Mark Turner, M.D. 2002-2004 M.D., Plymouth, UKConsultant, Bristol Royal Infirmary

Project: “Connexin43 phosphorylation and regulation by ischemia”

Jian Qin Wei, M.D. 2000-present M.D., Medical College of Shanghai, TieDao Univ.Postdoctoral Research Associate, NIH R-01 supported

Project: “Genetic and molecular physiology of transcription coactivator p300”

27


Todd Miller, Ph.D. 2001-present Ph.D., University of Miami, Senior Scientist, Specialty Laboratories, Inc., Valencia, CA

Project: “Genotype-Phenotype Correlations in Long QT Syndrome”

Alex Llanos, M.D. 2004- 2006 MD and Resident in Medicine, University of MiamiCardiology Fellow, Emery University

Project: “Induction of p300 expression in human heart failure and myocardial ischemia”

Claudia Rodrigues PhD. 2005- Ph.D., Federal University of Rio de JaneiroPostdoctoral Fellow, NIH Training Grant in Cardiovascular Signalling

Project: “A novel model of aging caused by haploinsufficiency of transcription coactivator p300”

Lina Shehadeh, Ph.D. 2005- Ph.D., Florida Atlantic UniversityNIH Kirchstein NRSA Award

Project: “Novel algorithms for microarray data analysis applied to cardiac hypertrophy”

Dylan Steen, MD 2006-present Instructor in Medicine, UM Housestaff R3Project: “Growth and oxidant susceptibility of cardiac stem cells”

Pre-doctoral Trainees:

Tatiana I. Slepak, B.S. 1997-2001 B.S., Moscow, RussiaResearch Scientist, John T. Macdonald Center for Genetics, University of Miami

Project: “Cardiac transcriptional activation partners for p300”

Mark Turner, M.D. 1998-2004 M.D., University of Wales; earned Ph.D. from my laboratory, granted at University of Wales.Consultant in congenital heart diseases, University Hospital, London, UK

Project: “Connexin43 regulation during myocardial hypoxia and reoxygenation”

Thanh Tranh, Ph.D. 2000-2006 B.S., Tufts University; PhD, Univ of MiamiGraduate Student, NIH Cardiovascular Training Grant, AHA Predoctoral FellowshipPostdoctoral Fellow, Novartis Institute for Biomedical Research, Cambridge, MA

Project: “Mechanisms of Jun kinase-mediated cardiac myocyte cytoprotection”

Ana G. Cristancho 2003-2004 Earned B.S. from University of Miami while in labM.D.-Ph.D. degree program, University of Pennsylvania

Project: “A novel model of aging in mice”

28


Mauricio Montezuma, 2002-2003 MD, Universidad del Valle, Cali, Columbia Postdoctoral fellow, Universidad del Valle, Cali, Columbia

Project: “Candidate genes in right ventricular dysplasia”

Brian Weber 2000-2002 Coral Gables High School StudentIntel High School Student Scholar

Project: “Genetic testing in Long QT syndrome”

James Mitrani 2001-2004 Hillel SchoolIntel High School Student Scholar

Project: “p300 levels as a determinant of hypertrophy in the cardiac myocyte”

Dane Thomas 2002-2003 Sophomore, University of Florida, Gainesville, FLProject: “Models of cardiac hypertrophy and pressure overload”

Raul Blanco 2002 Summer Cardiovascular Grant Predoctoral FellowProject: “Genetic testing for mutations in the sodium channel SCN5A”

Niberto Moreno, B.S. 2001-2002 B.S., University of MiamiMedical student year 4, University of Miami

Project: “Manifestations of Long QT syndrome in the preterm infant”

Hooshang Bolooki, Jr. November 2002 Medical Student year 4, UMSMProject: “Human Mutations in Cardiac Troponin T”

Maria Gallego Oct-Dec 2002 Medical Student year 4, UMSMProject: “A novel Long QT mutation”

Leon McCaskill September 2002 Medical Student year 4, UMSMProject: “The LQT1 Y1102 polymorphism and frequency in African Americans”

Katherine Lee 2004 Summer Senior at Stanford Univ., Stanford, CAProject: “Validating blood cell RNA as a source for genetic testing material”

Arieh Fox 2004 -2005 Medical Student year 1, UMSMProject: “Screening for dilated cardiomyopathy mutations using blood RNA”

Yehuda Deutsch 2004-2005 Medical Student year 1, UMSM.Project: “Cardiac myosin binding protein-C expression and genotyping in peripheral blood”

Kerline Ductan 2005-Summer Medical Student, 2nd year, University of MiamiProject: “Screening for Long QT1 Mutations”

29


Sam Weiss 2005-Summer Undergraduate Student, University of MiamiProject: “Screening for Mutations in the SCN5A Sodium Channel”

Tara Chang 2005-Summer Medical Student, 2nd year, University of VirginiaProject: “Apoptosis in a Mouse Genetic Model of Calcium Overload”

Harley Gould 2005-Summer Undergraduate Student, 1st year, Duke UniversityProject: “Bioinformatic applications in cardiovascular genetics”

Noam Koenigsberg 2005-2006 Medical Student, 1st year, UM Miller SMProject: “Novel genetic screen for laminopathies”

Jason Au Summer 2005 B.S., 2005, UM Medical Student, 1st yearProject: “Regulation of the p300 promoter in cardiac myocytes”

Erik Bernstein 2005-2006 Medical Student, 4th year, University of MiamiProject: “Genetics of Acquired Long QT Syndrome”

Melanie Adamsky Summer 2006 Undergraduate student, 2nd year, Cornell UniversityProject: “Genetic screening for sudden death genes”

Lindsay Mitrani 2006-present Hillel School, Intel Scholar competitorProject: “Immunohistological characterization of cardiac stem cells”

Anisha Gupta 2006-present Undergraduate student, 1st year, U. MiamiProject: “Expression of p300 target genes”

Sasha Sitahal 2006-present Undergraduate student, 2nd year, U. MiamiProject: “Expression profiling in cardiac hypertrophy”

Yousuf Ali Fall 2006 Rotation IBS graduate student, U. MiamiProject: “Sizing the apoptosome by chromatography”

Emily Heenan Fall 2006 Rotation Pharmacology graduate student, UMProject: “Effects of siRNA inactivation of p300 in normal and transformed cells”

Ines Chopra Winter 2006 Rotation Pharmacology graduate student, UMProject: “Differentiation potential of cardiac stem cells”

Sumit Jain Winter 2006 Rotation IBS graduate student, UMProject: “Purification of an Apaf-1-Jun kinase complex”

Salil Sharma Spring 2007 Rotation Pharmacology graduate student, UMProject: “Lentiviral modification of cardiac stem cells”

Sanjeev Sirpal Spring 2007 Rotation MD-PhD studentProject: “Neural cell adhesion molecule as a modulator of hypertrophy”

Karel Calero 2007- MSIV Elective in Pharmacology Research, UMProject: “Cardiogenic potential of an adult ventricular stem cell clone”

30


Dylan Steen 2006- Medical Resident III, research electiveProject: “Ischemic and Cell cycle regulation of p300”

John D. Clark, III 2007- M.D.-PhD candidate

-------Dissertation Committee for Physiolopogy and Biophysics Student Gayathri Venkatraman(completed)

Dissertation Committee for Physiology & Biophysics Student Yuhui Wen, (June 30, 2006 – present)

Dissertation Committee for Molecular and Cellular Pharmacology Student David Dweck (October 16, 2006 – present)

SERVICE

30. University committee and administrative responsibilities:

Scientific Advisory Committee (1999-2001)

Pharmacology Faculty Advisory Committee (1998-2000)

Sylvester Cancer Center Intramural Grant Review Committee (1999-present)

School of Medicine New Curriculum Subcommittee (Cardiovascular) (1999-2001)

Search Committee, Dept. of Genetics John T. Macdonald Foundation Center Director (2000-02)

Medical School Faculty Council (June 2001-present)Subcommittee on Research Priorities (2001 – 2002)Subcommittee on Parental Leave Policy (2003)Subcommittee on UMMG Part Time Status and Work Relief (2003)Council Representative to Library Committee (October 2005 – present)Member, Search Committee for Head of Library Services (2006-present)

Member, Chair Search Committee, Department of Pediatrics, (2001-2002)

Chair, Faculty Search Committee, Dept. of Molecular and Cellular Pharmacology, (2004-2005)

MD-Ph.D. Committee, Member (2004 – 2007)

Facilities and Planning Committee, Member (2005)

Faculty Council Promotion and Tenure Subcommittee (2007)

Appointment, Promotion and Tenure Committee, Member (June 1, 2006 – May 31, 2009)

31


Member, Dean’s Research Cabinet (2006-present)

Medical Library Director Search Committee (2006-2007)

Faculty Senate Hearing Panel, (2004-present)

31. Community Activities:

Soprano I, University of Miami Frost Collegium Musicum, Donald Oglesby, director (2000-present)

Representative Performances (last 5 years):

G.F. Handel, Coronation Anthems Nos.1-4 and Chandos Anthem No. 8, Nov. 2002

J.S. Bach, The Passion According to St. John, March 2003

J.S. Bach, Cantata 147, “Herz und Mund und Tat und Leben” October 2003.

Marc-Antoine Charpentier, Messe de Minuit pour Noël, and Noël variations by LaLande, Balbastre, and other French baroque composers, Miami, FL, Nov. 2004

J.S. Bach, Mass in B Minor, April 2005 Ranked in Miami Herald Top 10 Musical Performances of 2005(http://www.miami.com/mld/miamiherald/entertainment/music/11490443.htm)

Franz Schubert, Mass #4 in C Major, November 2005

Tomas Luis de Victoria, Lamentations of Jeremiah and Tenebrae Responsories, April 2006

Evensong Service in celebration of the 110th anniversary of Trinity Episcopal Cathedral, Miami, FL- works by Palestrina, Weelks, Tchaikovsky, Stanford, and others.

Tomas Luis de Victoria and others, Good Friday Tenebrae service, Trinity Episcopal Cathedral, April 2007

G.F. Handel, “Saul” oratorio, April 2007, Temple Israel, Miami, FL

Founding member, Grove Consort

Debut performance June 25, 2006 at Books & Books, Coral Gables, FL. Works by Monteverde, Wilbye, Telemann, and Handel.

Soprano I, St. Stephen's Episcopal Church Adult Choir, Coconut Grove, FL (1997-2001, 2005-)

Soprano I, Plymouth Congregational Church, Coconut Grove, FL (2001- present)

Coral Gables High School Band Boosters, 2000-2004

CBS, Channel 4 Panel, Ask the Experts - Feb. Heart Month Call-in (3 hours), Florida Heart Research Institute, February 5, 2004.

32


Lighthouse Point Yacht and Racquet Club, invited speaker, along with Dr. Steven E. Lipshultz, on “Adult Aspects of Cardiology,” (~ 3½ hours) January 12, 2006.

33